TERESA OMWENGA: Open Payments
NPI 1578286688 · WAYNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$612 in 17 payments from 7 companies in 2025. Trend: 2023 $133 · 2024 $301 · 2025 $612
Food & beverage: $501Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $348 |
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
| Neurocrine BioSciences, Inc. | 3 | $62 |
| Alkermes, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
Products named: REXULTI, ABILIFY MAINTENA, INGREZZA, ARISTADA, LYBALVI, ABILIFY ASIMTUFII, CAPLYTA, COBENFY.
Industry payments across NJ — which companies pay providers there.
